PubMed中文版

检索结果 3681
原始关键字 阿尔茨海默病 治疗 
转化关键字 TITLE_ABS:("Alzheimer disease" treatment) AND SRC:MED 
全部
标题/摘要
作者
按最近排序
按相关度排序
按日期排序
影响因子
出版日期
文献类型
物种
隐藏指标

文献列表

翻译标题
PubMed ID 41240389
发表日期 2026-08-01
作者 Jahanmehr D, Ahmadi A, Fadaei M, Sangi Nasab Lahijan A, Shafiee Sabet M, Kalantari Dehaghi H, Asadi-Golshan R.
文献标题 The Ketogenic Diet: A Possible Intervention for Improving Hippocampal Function in Neurological Disorders.
原始出处 Nutr Rev
影响因子 4.9   期刊引文指标 0.73
PubMed ID 42411945
发表日期 2026-07-06
作者 Nakamura Y, Tsushio T, Tanahashi M, Suganami H, Omori T, Nishiyama K, Aoki H, Nagakura N.
文献标题 Post Hoc Subgroup Analysis by Disease Severity in a Non-Inferiority Trial of Donepezil 27.5 mg Transdermal Formulation in Japanese Patients With Mild-to-Moderate Alzheimer Disease.
原始出处 Alzheimer Dis Assoc Disord
影响因子 1.4   期刊引文指标 0.6
PubMed ID 41824288
发表日期 2026-07-01
作者 Saad HM, Atef E, Aboushouk AA, Waheeb TS, Elsayed AE, Mohammed SAA.
文献标题 Cross-talk between pyroptosis and miRNAs in Alzheimer disease neuropathology, therapeutic targeting of NLRP inflammasomes, and recent advances in nanoparticle-targeted therapy.
原始出处 J Neuropathol Exp Neurol
影响因子 3   期刊引文指标 0.96
PubMed ID 42202980
发表日期 2026-05-26
作者 Sánchez-Valle R, Alcolea D, Amer Ferrer G, Balasa M, Casado Naranjo I, Fortea J, Lladó A, Lleó A, Montes AM, Martinez Lozano L, Martínez-Lage P, Matias-Guiu JA, Mendioroz M, Perez Martinez DA, Ripoll GP, Riverol M, Sanchez-Juan P, Bondía HV, Spanish Society of Neurology’s Behavioural Neurology, Dementia Study Group working group for the appropriate use of anti-amyloid monoclonal antibody treatment.
文献标题 Appropriate use recommendations of the Spanish Society of Neurology's Behavioural Neurology and Dementia Study Group on anti-amyloid antibodies in the treatment of Alzheimer disease.
原始出处 Neurologia (Engl Ed)
影响因子
PubMed ID 41926104
发表日期 2026-05-01
作者 Devanand DP, Wei R, Qian M.
文献标题 Treatment of Early Symptomatic Alzheimer Disease With Valacyclovir-Reply.
原始出处 JAMA
影响因子 55   期刊引文指标 11.47
PubMed ID 41926105
发表日期 2026-05-01
作者 Kosaka M, Kami M.
文献标题 Treatment of Early Symptomatic Alzheimer Disease With Valacyclovir.
原始出处 JAMA
影响因子 55   期刊引文指标 11.47
PubMed ID 41881052
发表日期 2026-03-25
作者 Noguchi-Shinohara M, Ono K.
文献标题 Successful Amyloid Removal by Donanemab Treatment in a Female Patient With Alzheimer Disease: A Case Report.
原始出处 Neurology
影响因子 8.5   期刊引文指标 2.54
PubMed ID 42015793
发表日期 2026-04-01
作者 Gao L, Watson R, Yassi N.
文献标题 Cost-Effectiveness of Donanemab for Early Alzheimer Disease in Australia.
原始出处 Med J Aust
影响因子 8.5   期刊引文指标 1.56
PubMed ID 41405876
发表日期 2026-02-10
作者
文献标题 Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: Research Summary.
原始出处 JAMA
影响因子 55   期刊引文指标 11.47
PubMed ID 41667287
发表日期 2026-03-04
作者 Casper A, Bolin J.
文献标题 Alzheimer Disease and the Utility of PET.
原始出处 J Nucl Med Technol
影响因子 1.3   期刊引文指标 0.42
PubMed ID 41575410
发表日期 2026-01-23
作者 Neth BJ, Graff-Radford J, Cogswell PM, Johnson DR, Botha H, McCarter SJ, Jones DT, Conkins MM, Hardin DB, Spence JJ, Rhegness CL, Allen LA, Coburn RP, Pounders JD, Burkett BJ, Pillai JJ, Day GS, Graff-Radford NR, Lachner C, Messina SA, Jain MK, Stricker NH, Machulda MM, Fields JA, Boots EA, Aduen PA, Barnard LR, Remold MA, Anderlik AM, Asleson KM, Martin LL, Klaassen JA, Larsen JJ, Algeciras-Schimnich A, Bornhorst JA, Rumilla AM, Jack CR, Boeve BF, Knopman DS, Petersen RC, Ramanan VK.
文献标题 Establishing an Alzheimer Disease Therapeutics Clinic: Experience From a Year of Evaluations.
原始出处 Mayo Clin Proc
影响因子 6.7   期刊引文指标 1.6
PubMed ID 41312794
发表日期 2025-11-28
作者 Healy M, Thomas S, Brodtmann A.
文献标题 Magnetic resonance imaging eligibility for anti-amyloid monoclonal antibody treatment for Alzheimer disease: a single-centre retrospective review for service planning.
原始出处 Intern Med J
影响因子 1.5   期刊引文指标 0.47
PubMed ID 40340060
发表日期 2025-01-01
作者 Fisher A, Levey AI.
文献标题 CNS muscarinic receptors and muscarinic receptor agonists in Alzheimer disease treatment.
原始出处 Handb Clin Neurol
影响因子
PubMed ID 39570769
发表日期 2024-11-20
作者 Shuja MH, Imran H, Abid M, Ibrahim Ahmed F.
文献标题 Evaluating Donanemab: Advances and Challenges in Alzheimer Disease Treatment.
原始出处 Am J Ther
影响因子 2.5   期刊引文指标 0.61
PubMed ID 39792495
发表日期 2024-11-01
作者 Espay AJ, Espay AJ.
文献标题 From Europe to the World: EMA's Leadership in Alzheimer Disease Treatment.
原始出处 Am J Ther
影响因子 2.5   期刊引文指标 0.61
PubMed ID 39283851
发表日期 2024-09-01
作者 Jaqua EE, Tran MN, Hanna M.
文献标题 Alzheimer Disease: Treatment of Cognitive and Functional Symptoms.
原始出处 Am Fam Physician
影响因子 3.5   期刊引文指标 1.63
PubMed ID 38175625
发表日期 2024-02-01
作者 Sutton SS, Magagnoli J, Cummings TH, Hardin JW, Ambati J.
文献标题 Alzheimer Disease Treatment With Acetylcholinesterase Inhibitors and Incident Age-Related Macular Degeneration.
原始出处 JAMA Ophthalmol
影响因子 9.2   期刊引文指标 3.81
PubMed ID 37655700
发表日期 2023-09-01
作者 El Alaouy MA, Alaqarbeh M, Ouabane M, Zaki H, ElBouhi M, Badaoui H, Moukhliss Y, Sbai A, Maghat H, Lakhlifi T, Bouachrine M.
文献标题 Computational Prediction of 3,5-Diaryl-1H-Pyrazole and spiropyrazolines derivatives as potential acetylcholinesterase inhibitors for alzheimer disease treatment by 3D-QSAR, molecular docking, molecular dynamics simulation, and ADME-Tox.
原始出处 J Biomol Struct Dyn
影响因子 2.4   期刊引文指标 0.66
PubMed ID 37422087
发表日期 2023-07-07
作者 Jeremic D, Jiménez-Díaz L, Navarro-López JD.
文献标题 Targeting epigenetics: A novel promise for Alzheimer's disease treatment.
原始出处 Ageing Res Rev
影响因子 12.4   期刊引文指标 1.68
PubMed ID 33390886
发表日期 2020-12-18
作者 Zhou Y, Chen Y, Xu C, Zhang H, Lin C.
文献标题 TLR4 Targeting as a Promising Therapeutic Strategy for Alzheimer Disease Treatment.
原始出处 Front Neurosci
影响因子